US loss of exclusivity · Immunology
Enbrel
Amgen
2029
US biosimilars from
2025
Today: 2026
2037
2025 worldwide sales
$2.2B
Date basis
Settlement / court date
US biosimilars
Approved, waiting to launch
Medicare price
−67% from 2026
Pharma Patent Cliff
by readouts.io
Data checked 24 October 2026 ·
Full Enbrel timeline →